Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 9/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT5A | Q9NQR1 | 2/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.30 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211480 | 1.00 | KDM1A (0.33) | KDM1ARCOR1EHMT2KDM4EALDH1A1 | |
| SCHEMBL35210881 | 1.00 | KDM1A (0.33) | KDM1ARCOR1EHMT2KDM4EALDH1A1 | |
| SCHEMBL35211452 | 0.90 | CCNT1 (0.34) | KDM4EALDH1A1P2RY12 | |
| SCHEMBL35211308 | 0.90 | CCNT1 (0.34) | KDM4EALDH1A1P2RY12 | |
| SCHEMBL35210838 | 0.90 | CCNT1 (0.34) | KDM4EALDH1A1P2RY12 | |
| SCHEMBL35211141 | 0.88 | DPP4 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL35210755 | 0.88 | DPP4 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL35211770 | 0.88 | DPP4 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL35211140 | 0.84 | ALDH1A1 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL35210835 | 0.84 | ALDH1A1 (0.36) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | KDM1A 4369/4885RCOR1 2730/4885EHMT2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.